NetworkNewsBreaks – Sorrento Therapeutics, Inc.’s (NASDAQ: SRNE) Pain Subsidiary Reports Positive Data from Adhesion Study of ZTlido™; Shares Higher
Shares of Sorrento Therapeutics (NASDAQ: SRNE) are up 7% mid-day after the company’s pain subsidiary, SCILEX Pharmaceuticals, released positive data regarding its lead investigational product, ZTlido™. During a recently completed comparative adhesion performance study to support the market authorization application (MAA) in the EU, ZTlido™ demonstrated superior adhesion versus the EU reference product, Versatis®. SCILEX said it plans to resubmit the New Drug Application for ZTlido™ to the FDA and the MAA to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in the second half of 2017. "We are pleased to report our noteworthy data. We believe…